Please login to the form below

Not currently logged in
Email:
Password:

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

Maura Dickler is set to join Lilly Oncology as VP of late phase development on May 7.

She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine Service within its Department of Medicine.

In her new role at Lilly Oncology she will report to senior vice president, global development and medical affairs Levi Garraway.

He said: "Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly."

In addition to her role at Sloan Kettering, Dr Dickler concurrently serves as associate professor of medicine at New York’s Weill Cornell Medical College.

15th March 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....